Arch Venture sets its sights on raising $600M for Fund X
Bob Nelsen’s VC group Arch Venture Partners has filed paperwork with the SEC expressing its plans to raise $600 million for its tenth fund — its biggest ever. The announcement comes at a time when the biopharma world is attracting an explosive level of venture capital as Big Pharma becomes increasingly dependent on smaller players for innovation. So far no capital has been raised for Fund X according to the SEC filing posted on Monday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.